Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DTC Advertising: FDA To Follow The Eyeballs In Study Of Risk Perception

This article was originally published in The Pink Sheet Daily

Executive Summary

Fictional obesity product to determine how consumers perceive both superimposed text of risk information and the MedWatch statement; study cost is $299,382.

You may also be interested in...



TV Drug Advertising Study Targets Those With Limited Or No Internet Use

US FDA will assess value of including 1-800 number and print ad in broadcast commercials; it is among 42 direct-to-consumer studies the agency has undertaken, 13 of which are in progress.

FDA’s Biggest DTC Advertising Study Eyes Online Promotion

The agency has 11 research projects under way, including a $2 million study of online Rx drug promotion; pharma spending on direct-to-consumer advertising declined in 2012 with biggest spends on Cymbalta and Cialis ads.

Pharmacies Likely To Cease Prescribing COVID-19 Therapeutics With End Of Public Health Emergency

Existing emergency use authorizations to remain in effect and FDA may continue to issue new ones. Pfizer and Merck are moving to transition Paxlovid and Lagevrio to full approval as FDA allows prescribing without a positive COVID test first.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS077399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel